10x Genomics Inc
For the period ended Dec 31, 2024. Filed Feb 13, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 13, 2025
TXG$62.90-3.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Loss
(In thousands)
| December 31, | |||
|---|---|---|---|
| 2024 | 2023 | 2022 | |
| Net loss | $(182,627) | $(255,099) | $(166,000) |
| Other comprehensive income (loss), net of tax: | |||
| Unrealized gains (losses) on available-for-sale marketable securities | 206 | 2,210 | (4,116) |
| Realized loss on available-for-sale marketable securities reclassified into net loss | 3 | 1,718 | — |
| Foreign currency translation adjustment | (273) | (22) | (241) |
| Other comprehensive income (loss), net of tax | (64) | 3,906 | (4,357) |
| Comprehensive loss | $(182,691) | $(251,193) | $(170,357) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.